Botanix News Hub
Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
The Australian Government has published the Final Progress Report for Australia’s First National Antimicrobial Resistance Strategy 2015–2019 detailing its efforts to limit the incidence of antimicrobial resistance (AMR) in Australia.
The report highlights activities implemented between 2017 and 2019 in the human and animal health, food production and the environment.
Looking ahead, the Australian Government last year announced more than $22.5 million over four years in the 2020–21 Budget to implement an effective strategic framework for addressing AMR.
Botanix supports all efforts by the government and industry to address this pressing global health emergency. We are proud to be doing our part in the development of our BTX 1801 antimicrobial platform program too – most recently, we published world-first human data showing that our synthetic CBD-based ointment/gel formula can effectively eradicate Staphylococcus Aureus.
Botanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, presented at the ASX Small and Mid-Cap Conference today.
View the presentation here:
Article extract | “Novartis’ acquisition represents a double-down on an antibiotics field facing an existential crisis from resistant “super bugs” that have sent most major drugmakers running for the hills — including Novartis, which dumped its antibiotic R&D program in 2018. But adding ever-greater volume to their generic antibiotics portfolio could offer Novartis some bottom-line value in the dwindling space.”
Click through to read the full article on Endpoints News.
‘A huge acquisition in the international medical cannabis sector is set to give tailwinds to several ASX-listed marijuana companies, Scott Power says.
Ireland-based Jazz Pharmaceuticals (NASDAQ:JAZZ) this week agreed to buy cannabinoid drugmaker GW Pharmaceuticals (NASDAQ:GWPH) for $US7.2 billion ($9.4 billion) – a 50 per cent premium to GW’s closing price on Tuesday.’
Click through to read the full article on Stockhead.
GW Pharma $GWPH, the UK biotech that caused a sensation of sorts with the approval of the world’s first cannabinoid med, is being bought out.
Jazz Pharmaceuticals came up with the winning number, agreeing to acquire GW for a total of $7.2 billion — $6.7 billion net of cash. GW agreed to a price of $200 cash and $20 in stock for the acquisition. This is the second biotech M&A deal of the week, which will likely portend more such deals to come.’
Click through to read the full article on Endpoints News here.
‘The Botanix Pharmaceuticals (ASX:BOT) share price has returned from its trading halt with a bang on Wednesday.
In morning trade, the clinical stage synthetic cannabinoid company’s shares are up 31% to a record high of 19 cents.’
Click through to read the full article on The Motley Fool.